🎥 Missed UEG Week 2026? No problem!
With high5immunology.TV, you can catch up on the key highlights from this year's congress – concise, scientifically sound, and relevant to clinical practice.
Explore the latest clinical trial data, key abstracts, and expert perspectives on developments in gastroenterology and digestive health, including inflammatory bowel disease, liver diseases, and other important areas of gastroenterology.
Our experts bring together the most relevant congress insights to help you stay up to date with the latest research and clinical developments.
👉 Explore the highlights: high5immunology.tv/ibd/ueg-w…#UEGWeek2026#UEGWeek#IBD#Gastroenterology#DigestiveHealth#IBD#InflammatoryBowelDisease#Hepatology#ClinicalTrials#MedicalEducation#high5immunologyTV
🎥 Welcome to UEG Week 2026!
In this special message, Alexander Moschen, MD, invites you to explore the latest scientific highlights from this year's congress on high5immunology.TV.
From key study results to expert analyses and congress abstracts, our platform brings together important developments in gastroenterology and digestive health – presented by leading international experts.
Discover the latest insights from UEG Week 2026, with expert perspectives designed to support clinical
practice.
👉 Explore the highlights: high5immunology.tv/ibd/ueg-w…#UEGWeek2026#UEGWeek#Gastroenterology#DigestiveHealth#ClinicalResearch#ClinicalTrials#MedicalEducation#high5immunologyTV
🎥 Behind the Scenes | UEG Week 2026
A little behind-the-scenes look at our work here at UEG Week in Barcelona! 🇪🇸
Together with leading experts, we're bringing you the latest congress insights and key scientific updates on Crohn’s disease (CD), inflammatory bowel disease (IBD) and ulcerative colitis (UC).
✨ The wait is almost over! Starting tomorrow, October 20, you can explore the latest findings and expert insights on high5immunology.TV.
👉 Stay tuned: high5immunology.tv/#UEGWeek2026#UEGWeek#BehindTheScenes#CrohnsDisease#IBD#UlcerativeColitis#Gastroenterology#high5immunologyTV
🎥 Behind the Scenes | UEG Week 2026
Barcelona became the meeting point for the gastroenterology community this weekend – and we're here on site! 🇪🇸
Our team is capturing exciting insights and the latest congress highlights for you. Look forward to reports from our experts, coming your way on October 20 on high5immunology.TV.
📍 Reporting live from Barcelona – stay tuned!
#UEGWeek2026#UEGWeek#Gastroenterology#MedicalEducation#BehindTheScenes#high5immunologyTV
🎥 Behind the scenes at EULAR 2026 in London!
While the latest breakthroughs in rheumatology and immunology are being presented at the congress, our team is already hard at work behind the camera. Together with leading international experts, we are presenting the most exciting study results, key congress highlights, and their relevance for clinical practice.
Stay tuned for concise congress summaries, expert perspectives, and the most important take-home messages from EULAR 2026.
📅 Available June 6th 2026, free of charge, on high5immunology.TV – exclusively for healthcare professionals.
#EULAR2026#EULAR#Rheumatology#Immunology#AutoimmuneDiseases#ClinicalTrials#PrecisionMedicine#MedicalEducation#ImmunologyResearch#high5immunologyTV
All high5oncologyTV ASCO 2026 reports are now available on demand.
🎥 Expert coverage of:
• Breast Cancer
• GU Oncology
• Lung Cancer
✅ Free access
✅ On demand
✅ For healthcare professionals
Watch now:
high5oncology.tv/meeting-cov…#ASCO26#Oncology#high5oncologyTV
The first reports from our high5oncologyTV ASCO 2026 coverage are now live.
🎥 Expert analysis on:
• Breast Cancer
• GU Cancers
• Lung Cancer
✅ Free
✅ On demand
✅ Directly from Chicago
Watch now and stay up to date with the latest ASCO 2026 data: high5oncology.tv/meeting-cov…#ASCO26#Oncology#high5oncologyTV
The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC .
A snapshot of what will shape LUNG oncology at #ASCO26 👇
🔹 HARMONI-6 — Ivonescimab + chemo vs tislelizumab + chemo in sqNSCLC (OS, Ph3)
🔹 LIBRETTO-432 — Adjuvant selpercatinib in RET+ NSCLC (EFS, Ph3)
🔹 WU-KONG28 — Sunvozertinib vs chemo in EGFR Ex20ins NSCLC (Ph3)
🔹 OPTITROP-LUNGO5 — Sac-TMT + pembrolizumab in PD-L1+ NSCLC (Ph3)
🔹 TRITON — Tremelimumab/durvalumab/chemo in STK11/KEAP1/KRAS-mut NSCLC
🔹 CROWN 7-year update — Lorlatinib vs crizotinib in ALK+ NSCLC
🔹 LORIN — Neoadjuvant lorlatinib in stage III ALK+ NSCLC
🔹 ACCELERET-LUNG — 1L pralsetinib in RET+ NSCLC
🔹 Silevertinib (BDTX-1535) — Non-classical EGFR-mut NSCLC
🔹 Concurrent CRT + durvalumab in ES-SCLC (Phase III)
Leads
@HHorinouchi@UOzkerim@WeOncologists
Senior Faculty
@GlopesMd@StephenVLiu@peters_solange@CharuAggarwalMD@MartinReck2@christine_lovly
Participating AF
@DrMirallas
Pinging faculty
@bmassutis@UmbertoMalapel1@jillfeldman4@bensolomon1@VanitaNoronha@DrSanjayPopat@DrJNaidoo@Latinamd@JulienMazieres@TerriConneran@BRicciutiMD